Seratrodast is primarily used as a selective thromboxane A2 receptor antagonist. It is commonly prescribed for the treatment of bronchial asthma, as it helps to reduce airway inflammation and bronchoconstriction. By inhibiting the action of thromboxane A2, it prevents the narrowing of airways and decreases the frequency of asthma attacks. Additionally, it is sometimes used in managing other inflammatory conditions due to its anti-inflammatory properties. Its effectiveness in improving respiratory function makes it a valuable option in asthma management, particularly for patients who may not respond well to other treatments.